Lituania - lituano - SMCA (Valstybinė vaistų kontrolės tarnyba)

sia ingen pharma - amlodipinas/valsartanas - plėvele dengtos tabletės - 5 mg/160 mg; 10 mg/160 mg - valsartan and amlodipine

Lituania - lituano - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 320 mg/25 mg; 320 mg/12,5 mg; 160 mg/12,5 mg; 80 mg/12,5 mg; 160 mg/25 mg - valsartan and diuretics

Unione Europea - lituano - EMA (European Medicines Agency)

bayer animal health gmbh - iron(iii) ion, toltrazuril - toltrazurilio, deriniai - kiaulės (paršeliai) - dėl vienalaikio prevencijos klinikiniai požymiai, coccidiosis (pvz., viduriavimas) į naujagimių paršelių ūkiuose su patvirtinta istorijos coccidiosis sukelia cystoisospora suis), ir prevencijos geležies stokos anemija.

Lituania - lituano - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - donepezilo hidrochloridas - plėvele dengtos tabletės - 10 mg; 5 mg - donepezil

Lituania - lituano - SMCA (Valstybinė vaistų kontrolės tarnyba)

egis pharmaceuticals plc - donepezilas - burnoje disperguojamos tabletės - 5 mg; 10 mg - donepezil

Unione Europea - lituano - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil hidrochloridas - kolorektaliniai navikai - antinavikiniai vaistai - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Lituania - lituano - SMCA (Valstybinė vaistų kontrolės tarnyba)

b.braun melsungen ag - gliukozė - infuzinis tirpalas - 100 mg/ml; 50 mg/ml - carbohydrates

Lituania - lituano - SMCA (Valstybinė vaistų kontrolės tarnyba)

pharmaswiss Česká republika s.r.o. - takrolimuzas - kietosios kapsulės - 1 mg; 0,5 mg - tacrolimus

Lituania - lituano - SMCA (Valstybinė vaistų kontrolės tarnyba)

johnson & johnson, uab - topiramatas - plėvele dengtos tabletės - 200 mg; 100 mg; 50 mg; 25 mg - topiramate

Unione Europea - lituano - EMA (European Medicines Agency)

mabxience research sl - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.